MALVERN,
PA - Solstice Neurosciences announced the
closing of a new round of financing totaling $85 million of both equity and
debt.
Highland Capital Management led the Series B round, with participation from
earlier investors Thomas, McNerney & Partners, Investor Growth Capital
Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners.
The proceeds will allow the company to pursue continued development for
treatments for movement disorders and cervical dystonia.